Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer

Oncotarget

Volumn 7, Issue 44, 2016, Pages 71608-71619

  Valenzuela Membrives, María del Mar ^a   Perea García, Francisco ^b   Sanchez Palencia, Abel ^b   Ruiz Cabello, Francisco ^b   Gómez Morales, Mercedes ^c   Miranda León, María Teresa ^c   Galindo Angel, Inmaculada ^c   Fárez Vidal, María Esther ^c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Flow cytometry; Immunohistochemistry; Immunological response; Lung cancer; Lymphocyte subsets

Indexed keywords

CD16 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER PATIENT; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; PHENOTYPE; SQUAMOUS CELL LUNG CARCINOMA; TUMOR DIFFERENTIATION; TUMOR INVASION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; LUNG TUMOR; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LUNG; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED;

EID: 84995514207     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12264     Document Type: Article

References (56)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83:584-94
2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. Nature Rev Cancer. 2012; 12:298-306
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. CA Cancer J. Clin. 2006; 56:106-30
4. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology. 2006; 6:295-307
5. Atreya I, Neurath M.F. Immune cells in colorectal cancer: Prognostic relevance and therapeutic strategies. Expert Rev Anticancer. 2008; 8:561-572
6. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22:215-222
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964
8. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29:610-8
9. Brambilla E, Le TeuffG, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipts M, Rosell R, Kratzke R, Popper H, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small cell lung cancer. J of Clin Oncol. 2016; 34:1223-30
10. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010; 22:231-7
11. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, et al. In situ cytotoxic and memory T cells predict outcome in patients with earlystage colorectal cancer. J Clin Oncol. 2009; 27:5944-51
12. Ronald J. deLeeuw, Sara E. Kost, Juzer A. Kakal, and Brad H. Nelson. The prognostic value of FoxP3+ tumorinfiltrating lymphocytes in cancer: a critical review of the literature. Clinical Cancer Research. 2012; 18:3022-29
13. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012; 75:95-101
14. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013; 73:3591-603
15. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nature Reviews Immunology. 2007; 7:329-39
16. Chan CJ, Andrews DM, Smyth MJ. Can NK cells be a therapeutic target in human diseases? Eur J Immunol. 2008; 38:2964-68
17. Cerwenka A, Falk CS, Watzl C. NK cells-from basic research to cancer therapy. Eur J Immunol. 2007; 37:1161-64
18. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or Adaptive Immunity? The Example of Natural Killer Cells Science. 2011; 331:44-9
19. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature Immunology. 2008; 9:503-1
20. Sun JC, Lanier LL. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? Eur J Immunol. 2009; 39:2059-64
21. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Björklund AT, Flodström-Tullberg M, Michaëlsson J, Rottenberg ME, Guzmán CA, Ljunggren HG, Malmberg KJ. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010; 116:3853-64
22. Béziat V, Descours B, Parizot C, Debré P, Vieillard V. NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs. PLoS One. 2010; 5:e11966
23. Jonsson AH, Yokoyama WM. Natural killer cell tolerance licensing and other mechanisms. Adv Immunol. 2009; 101: 27-79
24. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005; 436:709-713
25. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation. 2011; 121:3609-22
26. Brodin P, Karre K, Hoglund P. NK cell education: not an on-offswitch but a tunable rheostat. Trends in Immunology. 2009; 30:143-149
27. Elliott JM, Wahle JA, Yokoyama WM. HC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. Journal of Experimental Medicine. 2010; 207:2073-79
28. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. Journal of Experimental Medicine. 2010; 207:2065-72
29. Galon J, Angell HK, Bedognetti D, and Marincola FM. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 2013; 39:11-26
30. Dehghani M, Sharifpour S, Amirghofran Z, Zare HR. Prognostic significance of T cells subsets in peripheral blood of B cell non-Hodgkińs lymphoma patients. Med Oncol. 2012; 29:2364-71
31. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in nonsmall cell lung cancer. Cancer Immunol Immunother. 2011; 60:819-27
32. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005; 14:1269-73
33. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003; 9:606-12
34. Fracchia A, Pacetti M, Barberis M, Mura MA, Le Grazie C, Longhini E. Determination of T lymphocyte subpopulations in patients with lung cancer. A comparison between lung lavage and peripheral blood by monoclonal antibodies and flow cytometry. Respiration. 1987; 51:161-9
35. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348:74-80
36. Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol. 2015; 33:101-11
37. Chen C, Chen D, Zhang Y, Chen Z, Zhu W, Zhang B, Wang Z, Le H. Changes of CD4+CD25+FOXP3+ and CD8+CD28-regulatory T cells in non-small cell lung cancer patients undergoing surgery. Int Immunopharmacol. 2014; 18:255-61
38. Fu HY, Li C, Yang W, Gai XD, Jia T, Lei YM, Li Y. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem. 2013; 115:151-157
39. Ciebiada M, Kasztalska K, Gorska-Ciebiada M, Barylski M, Gorski P. Expression of IL-7 receptor in human peripheral regulatory T cells. Arch Med Sci. 2013; 9:555-60
40. Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, Baker E, Sutherland GR, Poindexter K, Birks C. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol. 1994; 153:3574-83
41. Mizumoto N, Kumamoto T, Robson SC, Sévigny J, Matsue H, Enjyoji K, Takashima A. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: Modulatory roles in inflammation and immune responsiveness. Nat Med. 2002; 8:358-365
42. Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, Yun B, Xia RL. Overexpression of CD39 and high tumoral CD39(+)/CD8(+) ratio are associated with adverse prognosis in resectable gastric cancer. Int J Clin Exp Pathol. 2015; 8:14757-64
43. Umansky V, Shevchenko I, Bazhin AV, Utikal J. Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunol Immunother. 2014; 63:1073-80
44. Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, Wherry EJ, Alter G, Goulder PJ, et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog. 2015; 11:e1005177
45. Bai A, Moss A, Rothweiler S, Longhi MS, Wu Y, Junger WG, Robson SC. NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2015; 9:6:8819
46. Strioga M, Pasukoniene, Characiejus D. CD8+ CD28-and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011; 134:17-32
47. Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E, Fietta AM. Foxp3 expressing CD4+ CD25+ and CD8+ CD28-T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 2006; 67:1-12
48. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology. 2013; 1;2:e25443
49. Gunderson AJ, Coussens LM. B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res. 2013; 319:1644-9
50. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. 2002; 110:1823-1830
51. Nimmerjahn F, Ravetch JV. Analyzing antibody-Fc-receptor interactions. Methods Mol Biol. 2008; 415:151-162
52. Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killercell diversity in mice and humans. Nature Reviews Immunology. 2007; 7:703-714
53. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. Journal of Experimental Medicine. 2006; 203:1033-43
54. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 2003; 24:603-9
55. Lee SH, Jo EJ, Eom JS, Mok JH, Kim MH, Lee K. Predictors of Recurrence after Curative Resection in Patients with Early-stage Non-small Cell Lung Cancer. Tuberc Respir Dis. 2015; 78:341-48
56. Goldstraw P. (Ed) Staging Manual in Thoracic Oncology. Editoral EXPress. 2015